129 related articles for article (PubMed ID: 436519)
1. Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report.
Bilgi C; Brown NE; McPherson TA; Lentle B
Chest; 1979 Jun; 75(6):685-7. PubMed ID: 436519
[TBL] [Abstract][Full Text] [Related]
2. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
MacGregor AB; Falk RE; Landi S; Ambus U; Samuel ES; Langer B
Can J Surg; 1977 Jan; 20(1):25-30. PubMed ID: 832200
[TBL] [Abstract][Full Text] [Related]
3. Detection of metastatic malignant melanoma by chest roentgenography.
Simeone JF; Putman CE; Greenspan RH
Cancer; 1977 May; 39(5):1993-6. PubMed ID: 858128
[TBL] [Abstract][Full Text] [Related]
4. Intralesional treatment of recurrent metastatic cutaneous malignant melanoma: a randomized prospective study of intralesional Bacillus Calmette-Guerin versus intralesional dinitrochlorobenzene.
Cohen MH; Jessup JM; Felix EL; Weese JL; Herberman RB
Cancer; 1978 Jun; 41(6):2456-63. PubMed ID: 657108
[TBL] [Abstract][Full Text] [Related]
5. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
Coates AS; Peters M
Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
[TBL] [Abstract][Full Text] [Related]
6. Uveitis and vitiligo associated with BCG treatment for malignant melanoma.
Donaldson RC; Canaan SA; McLean RB; Ackerman LV
Surgery; 1974 Nov; 76(5):771-8. PubMed ID: 4424743
[No Abstract] [Full Text] [Related]
7. Prognostic value of tuberculin and BCG immunoreactivity in stage I high-risk malignant melanoma (EORTC protocol 18781).
Henz BM; Macher E; Bröcker EB; Suciu S; Steerenberg PA; Jung E; Rümke P
Dermatology; 1996; 193(2):105-9. PubMed ID: 8884144
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy of melanoma with BCG: two fatalities following intralesional injection.
McKhann CF; Hendrickson CG; Spitler LE; Gunnarsson A; Banerjee D; Nelson WR
Cancer; 1975 Feb; 35(2):514-20. PubMed ID: 234291
[TBL] [Abstract][Full Text] [Related]
9. The immunologic and histopathologic changes of BCG-mediated tumor regression in patients with malignant melanoma.
Lieberman R; Wybran J; Epstein W
Cancer; 1975 Mar; 35(3):756-77. PubMed ID: 234295
[TBL] [Abstract][Full Text] [Related]
10. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
[TBL] [Abstract][Full Text] [Related]
11. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Deutschmann KE; Peter HH; Schultheis W; Deicher H
Tumori; 1977; 63(3):303-7. PubMed ID: 898298
[TBL] [Abstract][Full Text] [Related]
12. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
Peter HH; Deutschmann EM; Schultheis W; Deicher H
Dev Biol Stand; 1977 Apr 13-15; 38():537-40. PubMed ID: 344106
[TBL] [Abstract][Full Text] [Related]
13. Intralesional injection of the methanol extraction residue of Bacillus Calmette-Guerin (MER) into cutaneous metastases of malignant melanoma.
Krown SE; Hilal EY; Pinsky CM; Hirshaut Y; Wanebo HJ; Hansen JA; Huvos AG; Oettgen HF
Cancer; 1978 Dec; 42(6):2648-60. PubMed ID: 728866
[TBL] [Abstract][Full Text] [Related]
14. Randomized trial of Bacillus Calmette-Guérin (percutaneous administration) as surgical adjuvant immunotherapy for patients with stage-II melanoma.
Pinsky CM; Hirshaut Y; Wanebo HJ; Fortner JG; Miké V; Schottenfeld D; Oettgen HF
Ann N Y Acad Sci; 1976; 277(00):187-94. PubMed ID: 1069548
[No Abstract] [Full Text] [Related]
15. Treatment of disseminated malignant melanoma with high-dose oral BCG.
Varella AD; Bandiera DC; de Amorim AR; Calvis LA; Santos IO; Escaleira N; Gentil F
Cancer; 1981 Sep; 48(6):1353-62. PubMed ID: 7023654
[TBL] [Abstract][Full Text] [Related]
16. Fatal disseminated bacillus Calmette-Guerin infection and arrested growth of cutaneous malignant melanoma following intralesional immunotherapy.
de la Monte SM; Hutchins GM
Am J Dermatopathol; 1986 Aug; 8(4):331-5. PubMed ID: 3532854
[TBL] [Abstract][Full Text] [Related]
17. Results of administering B.C.G. to patients with melanoma.
Grant RM; Mackie R; Cochran AJ; Murray EL; Hoyle D; Ross C
Lancet; 1974 Nov; 2(7889):1096-100. PubMed ID: 4139404
[No Abstract] [Full Text] [Related]
18. Regression of pulmonary metastatic disease associated with intralesional BCG therapy of intracutaneous melanoma metastases.
Mastrangelo MJ; Bellet RE; Berkelhammer J; Clark WH
Cancer; 1975 Oct; 36(4):1305-8. PubMed ID: 1175129
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant BCG immunotherapy for malignant melanoma.
Paterson AH; Willans DJ; Jerry LM; Hanson J; McPherson TA
Can Med Assoc J; 1984 Oct; 131(7):744-8. PubMed ID: 6383591
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant BCG immunotherapy for stage I and II malignant melanoma.
Silver HK; Ibrahim EM; Evers JA; Thomas JW; Murray RN; Spinelli JJ
Can Med Assoc J; 1983 Jun; 128(11):1291-5. PubMed ID: 6342739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
